Text

Artesunat-Amodiakuin dan Klorokuin untuk Pengobatan Malaria Vivaks di Puskesmas Kopeta, Maumere, Nusa Tenggara Timur, 2007

---

Indonesia as a malaria endemic country is recommended to use Artemisinin-based Combination Therapy (ACT) for P. vivax malaria. Confirmation of Chloroquine resistant and ACT efficacy for P. vivax need to be investigated for supporting malaria treatment policy. Papua and East Nusa Tenggara (NTT) contribute the main malaria cases in Indonesia.

To evaluate efficacy and safety of Artesunate Amodiaquine (AsAq) as an ACT programme compared to drug Klorokuin (Cq) as a conventional for vivax malaria at Public Health Care in NTT. This was a clinical study, prospective, efficacy and safety evaluation of AsAq compared to Cq for malaria P.vivax subject and followed by 28 days, based on WHO protocol 2003. Intention to treat (ITT) and per protocol (PP) was performed to compare AsAq and Cq efficacy. Safety was evaluated based on the incidance or severity of clinical symptoms by 28 days of follow up.

Total of 100 P. vivax monoinfection suitable with the inclusion/exclusion criteria was randomized treated with AsAq or Cq. The 28 days efficacy of AsAq and Cq was 93.7% (95%CI: 83.8 – 97.9) versus 56.4% (95%CI: 50.1 – 75.9) with Log Rank (Mantel Cox)

---

Availability

Detail Information

Series Title

-

Call Number

Media Litbangkes, 24 (4) : 161-168

Publisher

Jakarta : Sekretariat Balitbangkes., 2014

Collation

8p

Language

ISBN/ISSN

0853-9987

Classification

-

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

AMODIAQUINE
PLASMODIUM VIVAX

Specific Detail Info

-

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment